Table 3. Selected studies of bispecific... | American Society of Hematology

Table 3.

Selected studies of bispecific T-cell engagers in lymphoma

BiTE	Target	Study phase	Patient population	Outcome(s)
Mosunetuzumab	CD20/CD3	I/Ib¹⁵	R/R B-cell NHL	CRS in 28.4% including 27.1% grade 1-2
				NAEs in 44% including 40.8% grade 1-2, headache (14.7%), insomnia (10.1%), and dizziness (9.2%)
				ORR of 64.1% and CR rate of 42.2% for indolent NHL, ORR of 34.7% and CR rate of 18.6% for aggressive NHLs
CD20-TCB	CD20/CD3	I¹⁷	R/R NHL	CD20-TCB monotherapy
				CRS in 55.1% including 22% grade 1 and 31% grade 2, pyrexia in 34.7% and neutropenia in 34.7%
				ORR of 47%, CR rate of 34% in aggressive NHL patient
	CD20/CD3	I/Ib¹⁸	R/R B-cell NHL	CD20-TCB with obinutuzumab
				AEs: anemia (21%), thrombocytopenia (21%), neutropenia (14%), pyrexia (14%), hypokalemia (14%)
				CRS in 57% of patients including 50% grade 1-2, rare NAEs
				ORR of 48% and CR rate of 43%

BiTE	Target	Study phase	Patient population	Outcome(s)
Mosunetuzumab	CD20/CD3	I/Ib¹⁵	R/R B-cell NHL	CRS in 28.4% including 27.1% grade 1-2
				NAEs in 44% including 40.8% grade 1-2, headache (14.7%), insomnia (10.1%), and dizziness (9.2%)
				ORR of 64.1% and CR rate of 42.2% for indolent NHL, ORR of 34.7% and CR rate of 18.6% for aggressive NHLs
CD20-TCB	CD20/CD3	I¹⁷	R/R NHL	CD20-TCB monotherapy
				CRS in 55.1% including 22% grade 1 and 31% grade 2, pyrexia in 34.7% and neutropenia in 34.7%
				ORR of 47%, CR rate of 34% in aggressive NHL patient
	CD20/CD3	I/Ib¹⁸	R/R B-cell NHL	CD20-TCB with obinutuzumab
				AEs: anemia (21%), thrombocytopenia (21%), neutropenia (14%), pyrexia (14%), hypokalemia (14%)
				CRS in 57% of patients including 50% grade 1-2, rare NAEs
				ORR of 48% and CR rate of 43%

CR, complete response; CRS, cytokine release syndrome; NAEs, neurologic adverse events; NHL, non-Hodgkin lymphoma; ORR, overall response rate; R/R, relapsed or refractory.